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Abstract
Background: Immigrants originating from intermediate and high HCV prevalence countries may be at increased
risk of exposure to hepatitis C infection (HCV) in their countries of origin, however they are not routinely screened
after arrival in most low HCV prevalence host countries. We aimed to describe the epidemiology of HCV in
immigrants compared to the Canadian born population.
Methods: Using the reportable infectious disease database linked to the landed immigration database and
several provincial administrative databases, we assembled a cohort of all reported cases of HCV in Quebec,
Canada (1998–2008). Underlying co-morbidities were identified in the health services databases. Stratum
specific rates of reported cases/100,000, rate ratios (RRs) and trends over the study period were estimated.
Results: A total of 20,862 patients with HCV were identified, among whom 1922 (9.2%) were immigrants.
Immigrants were older and diagnosed a mean of 9.8 ± 7 years after arrival. The Canadian born population
was more likely to have behavior co-morbidities (problematic alcohol or drug use) and HIV co-infection.
Immigrants from Sub-Saharan Africa, Asia and Eastern Europe had the highest HCV reported rates with RRs
compared to non-immigrants ranging from 1.5 to 1.7. The age and sex adjusted rates decreased by 4.9%
per year in non-immigrants but remained unchanged in immigrants. The proportion of HCV occurring in
immigrants doubled over the study period from 5 to 11%.
Conclusions: Immigrants from intermediate and high HCV prevalence countries are at increased risk for HCV
and had a mean delay in diagnosis of almost 10 years after arrival suggesting that they may benefit from
targeted HCV screening and earlier linkage to care.
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Background
Health care utilization, costs and mortality due to
hepatitis C infection are increasing in many low HCV
prevalence countries in North America and Europe
resulting in an enormous burden on society and health
care systems [1–8]. Undetected chronic infections
remain asymptomatic for decades until they progress to
chronic liver disease and liver cancer [9]. HCV is now
the leading infectious cause of death and the primary
indication for liver transplants in Canada and the US
[2, 3, 10, 11]. These sequelae are preventable through
early screening and providing highly effective therapy that
cures infection, stops the progression to liver disease and
decreases all-cause mortality [12, 13]. Despite the benefits
of curative therapy and recommendations for risk factor
based screening almost half of all HCV infected persons
in these low HCV prevalence countries remain undiag-
nosed [9, 14, 15]. Risk factor based programs recommend
screening for those at increased risk for HCV exposure
such as current or past intravenous drug use, those who
have received blood products prior to routine HCV
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screening of the blood supply, hemodialysis, and in-
carceration [16–18]. Identifying all HCV infected indi-
viduals and successfully linking them to care is
therefore an urgent priority to reverse the escalating
burden of HCV.
Immigrants living in low HCV prevalence countries
are a large underappreciated group that are dispropor-
tionately affected by HCV infection. Many were born
in intermediate and high HCV prevalence countries
and thus at increased risk to have been exposed to
HCV in their countries of origin [19, 20]. In inter-
mediate and high HCV prevalence countries HCV
infection are acquired primarily iatrogenically through
contaminated needles, medical procedures, or due to
the receipt of unscreened contaminated blood prod-
ucts whereas in low HCV prevalence countries, the
primary mode of transmission is through intravenous
drug use (IDU) [16–18, 21]. Many immigrants from
intermediate/high HCV prevalence countries will
therefore be missed in current risk factor based
screening programs. In certain low HCV prevalence
countries such as Japan and Italy, the HCV epidemi-
ology is more complex and reflects changing temporal
patterns of HCV transmission with high HCV rates in
older cohorts that were remotely infected through
iatrogenic transmission (eg. blood transfusions and
unsafe medical procedures), whereas recent infections
are occurring in those with percutaneous exposure
such as intravenous drug users, and/or among in-
carcerated individuals [9, 22, 23]. Recent estimates
suggest that the foreign-born population has a higher
HCV seroprevalence (~2%) compared to host populations
and account for a substantial proportion of HCV
cases (35–50% or more) in Canada and many European
countries, even though immigrants make up less than
20% of the population [15, 19, 24]. Despite this, im-
migrants are not routinely screened for viral hepatitis
before or after arrival in most host countries. In a
population-based cohort, we aimed to determine the
rates of newly reported HCV cases, the trend over
time, and behavioral risk factors for exposure to HCV
in immigrants as compared to the Canadian born
population. The objective of this study was to identify
immigrant groups who would benefit most from tar-
geted HCV screening and early linkage to care. These
data may ultimately be used to inform policy making
and health care planning.
Methods
We conducted a population-based retrospective study of
all reported cases of hepatitis C and their associated
health services in Quebec, Canada between January 1,
1998 and June 30, 2008 by linking three Quebec provin-
cial administrative databases.
Data sources
The Quebec public health mandatory reportable (notifi-
able) infectious disease (MADO) database in which all
laboratory confirmed cases of HCV are reported using
standard definitions since 1998 [25]. The majority of
laboratories began reporting HCV in 1998 even though
obligatory reporting of HCV came into effect in 2002.
The Régie de l’assurance maladie du Québec (RAMQ), is
the universal free health care plan in Quebec and covers
over 99% of the Quebec born and landed immigrant
population. RAMQ manages the following provincial
administrative databases; 1) the Quebec hospital dis-
charge database (MED-ECHO) in which discharge diag-
noses are coded using the International Classification of
Diseases, Ninth Revision (ICD-9) up until March 2006
and ICD-10 from April 2006 onward (ICD-10), 2) the
physician reimbursement claims (RAMQ-PB) for in-
patient and ambulatory medical services with visit diag-
noses classified with ICD-9 codes and 3) the provincial
prescription plan (RAMQ-Pharm) contains information
on all dispensed medications and covers ~50% of the
population. The Québec landed immigrant database
(MIDI) contains demographic information on all immi-
grants and refugees (~1,258,000) who have arrived and
were given permission to live in Quebec since 1985 [26].
Cohort assembly
All cases of chronic HCV present in the MADO data-
base between Jan 1, 1998 and June 30, 2008, were deter-
ministically linked to the RAMQ databases through a
unique health card number. All immigrants present in
the MIDI database from January 1, 1985 to June 30,
2008 were deterministically linked to the RAMQ demo-
graphic database thorough the presence of a unique
immigration number and allowed for classification of
cases as occurring in immigrants (who arrived between
1985 and 2008) or in non-immigrants.
Variables
All reported cases of chronic HCV present in the MADO
database were included. Chronic HCV included those
with either past or current (viremic) infection and were
defined as the presence of HCV antibody (anti-HCV)
detected by an enzyme immunoassay (EIA) confirmed by
a second test (a different EIA, RIBA, INNO-LIA or PCR),
or a very high level of anti-HCV antibodies not requiring a
confirmatory test, or a positive HCV RNA by reverse
transcriptase polymerase chain reaction (RT-PCR) [25].
Acute HCV cases were excluded. The MIDI database
included information on country of origin, date of arrival,
and immigrant class at time of landing. Countries of origin
were grouped into regions of origin as classified by the
World Bank (Additional file 1: Table A1) [27]. Immigra-
tion status at the time of acceptance as a permanent
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resident was classified as either a refugee or an immigrant.
Hepatitis C behavioral risk factors including problematic
drug use (both recreational and prescribed drugs) or
underlying co-morbidities such as problematic alcohol
use, alcohol-related liver disease, and HIV, occurring in
the year prior to HCV diagnosis were identified in the
MED-ECHO and RAMQ-PB databases through the pres-
ence of diagnoses classified by ICD-9/10 codes [28, 29].
Additional cases of drug use and HIV we identified
through the use of methadone or HIV specific medications
present in the RAMQ-Pharm database (Additional file 1:
Table A2).
Statistical analyses
Standard descriptive statistics were used when appro-
priate (t-test, Chi-2, and Fisher’s exact test). Rates of
reported HCV cases/100,000 with 95% confidence inter-
vals (CIs) for the entire study period and per year in im-
migrants and non-immigrants were estimated with a
Poisson distribution. Stratum-specific rates by age, sex,
region of origin, and immigration class for immigrants
and by age and sex for non-immigrants were also esti-
mated. Numerators were derived from the database pro-
duced in this study. The denominator was estimated
using census data for the population of Quebec in 1996,
2001, and 2006, with linear interpolation for the inter-
censal years. Rate ratios (RRs) and 95% CI of overall and
stratum specific rates of reported HCV cases in immi-
grants as compared to the Canadian-born population
were calculated with Poisson regression. The age and
sex adjusted trends of reported rates of HCV cases over
the study period were modeled with Poisson regression
in immigrants and non-immigrants, separately. To
estimate the impact of unlinked cases [19.8% of all cases
(N = 5255)] on the calculated rates and to determine if
the linkage was differential for immigrants and non-
immigrants, inverse probability weighting was used [30,
31]. Two separate models were constructed using age,
sex, address, and year of diagnosis from complete cases
as predictive variables for immigrant status. These vari-
ables were chosen as immigrants were older, less likely
to be male and to live in different neighbourhoods com-
pared to non-immigrants. Additional methods and
results are shown in the Additional file 1: Table A3. All
analyses were performed using SAS® 9.4 (SAS Institute
Inc., Cary, NC, USA).
Results
Between 1998 and 2008, 26 491 unique cases of chronic
HCV were identified in the MADO database. Of these,
20,862 cases were included in the final cohort; 1922
cases (9.2%) in immigrants and 18 940 cases (90.8%)
in non-immigrants (Fig. 1). A total of 5255 (19.8%)
cases did not link due to anonymous reporting by cer-
tain clinics or missing demographic or RAMQ num-
bers. Additional cases were excluded because episodes
occurred during a period of ineligibility for RAMQ
of > 6 months or prior to permanent resident status
(immigrants). Unlinked cases (19.8%) were slightly
younger (41 vs 43 years), more likely to be male and
to reside in certain regions such as Montreal, than
linked cases (Additional file 1: Table A4). They were
not found to be differentially distributed between
immigrants and non-immigrants after imputing with
inverse probability weighting. The RR was similar for
unweighted and weighted incidence; 0.85 (0.81–0.90)
vs 0.87 (0.84–0.91) (Additional file 1: Table A3). All
reported rates are therefore likely to be 20% higher
than estimated for both groups.
Demographic characteristics and comorbidities of
HCV cases are shown in Table 1. Cases in immigrants
were older than in non-immigrants and were less likely
to be male. Immigrant cases originated mainly from East
Asia and the Pacific region (23%), Eastern Europe and
Central Asia (14.7%), and the Middle East and North
Africa (13%). The mean time to diagnosis of HCV after
Fig. 1 Flow chart for hepatitis C cases identification and Cohorts’ creation
Greenaway et al. BMC Infectious Diseases  (2017) 17:140 Page 3 of 10
arrival in Quebec was 9.8 ± 7.0 years. There were signifi-
cant differences between the prevalence of comorbidi-
ties. The Canadian born population was significantly
more likely than immigrants to have behavioral co-
morbidities such as problematic alcohol or drug use and
to be HIV co-infected (Table 1). The prevalence of prob-
lematic drug use in immigrants was not significantly
different by country/region of origin or immigration
categories: the frequency of problematic drug use ranged
between 1% in East Asia to 4% in the Middle East and
North Africa, and was 2% overall for both refugees and
other immigrants.
Rates of reported cases of chronic hepatitis C
The rate of reported cases of HCV was higher in non-
immigrants compared to all immigrants [27.1 vs 23.2/
100,000, RR 0.85 (95% CI 0.80, 0.90)] (Table 2). Immi-
grants from low/intermediate income countries (ie.
excluding immigrants from Western Europe, the US,
Australia and New Zealand) however, had higher rates
compared to non-immigrants; 32.3/100,000 with a RR of
1.19 (95% CI 1.13, 1.25). Rates of reported HCV cases
adjusted for age and sex decreased by 4.89% per year in
non-immigrants between 1998 and 2008 whereas it in-
creased slightly by 0.27% per year in all immigrants
(Fig. 2). The proportion of all HCV cases occurring in
immigrants doubled during the study period; they
accounted for 5.1% of all cases in 1998 and 11.1% of all
cases in 2008. The overall reported rate of all HCV cases
present in the MADO database (includes both linked
and unlinked cases) between 1998 and 2008 was 33.9/
100,000 (95% CI 33.5, 34.3). Supplemental data for all
cases in the MADO database from 1991 to 2008 are
presented in the Additional file 1: Table A5.
Reported rates of all hepatitis C cases per year strati-
fied by sex are shown in Additional file 1: Figure A1.
Reported HCV rates in all immigrant females were
slightly higher over the study period compared to non-
immigrant females with overall rates of 21.1 and 17/
100,000 respectively [RR 1.25 (1.17–1.35)] (Table 2).
HCV rates were lower in all immigrant males compared
to non-immigrant males with overall rates of 25.3 and
Table 1 Demographic characteristics of chronic hepatitis C




(N = 18 940)
P-
value
Age at time of HCV diagnosis (years)
Mean (SD) 47.5 (15.1) 43.2 (13.3) <0.001
Age group (years)
< 15 11 (0.6) 104 (0.5) <0.001
15–19 17 (0.9) 297 (1.6)
20–29 133 (6.9) 2040 (10.8)
30–39 452 (23.5) 5114 (27.0)
40–49 588 (30.6) 6666 (35.2)
50–59 324 (16.9) 2705 (14.3)
60–69 193 (10.0) 1022 (5.4)
≥ 70 203 (10.6) 991 (5.2)
Sex
Female 891 (46.4) 6004 (31.7) <0.001
Male 1031 (53.6) 12,936 (68.3)
Residence area by public health region
Montréal 1488 (77.4) 7104 (37.5) <0.001
Montérégie 157 (8.2) 2674 (14.1)
Laval 105 (5.5) 747 (3.9)
Capitale-Nationale 52 (2.7) 1713 (9.0)
Laurentides 28 (1.5) 1582 (8.4)
Outaouais 32 (1.7) 905 (4.8)
Estrie 25 (1.3) 694 (3.7)
Mauricie et du Centre-du-
Québec
8 (0.4) 1132 (5.9)
Other regions 35 (1.8) 2389 (12.6)
Immigration category




East Asia and Pacific 443 (23.0)
Eastern Europe and Central
Asia
287 (14.9)




South Asia 181 (9.4)
Western Europe 167 (8.7)
Sub-Saharan Africa 152 (7.9)




Mean Time to diagnosis after
arrival (years) (SD)
9.8 (7.0)
Co-morbidities prior to diagnosis
Problematic alcohol use 29 (1.5) 2419 (12.8) <0.001
Table 1 Demographic characteristics of chronic hepatitis C
cases (1998–2008) in immigrants and non-immigrants
(Continued)
Alcohol-related liver disease 30 (1.6) 581 (3.1) 0.0003
Problematic drug abuse 47 (2.5) 4520 (23.9) <0.001
HIV 23 (1.2) 874 (4.6) <0.001
aOther categories included permanent residents who were workers,
spouses, children, and students
bCountries of origin regrouped according to the World Bank criteria [27].
Top 10 countries were Vietnam (226), Pakistan (128), Cambodia (123),
Romania (118), Haiti (111), Morocco (92), France (90), Egypt (60), Congo
(55), and Russia (36) accounting for 54% of all cases
Greenaway et al. BMC Infectious Diseases  (2017) 17:140 Page 4 of 10
37.8/100,000 respectively [RR 0.67; 95% CI 0.63–0.71].
Rates of HCV in non-immigrants males and females
both decreased over the study period whereas HCV rates
did not change in immigrant males and females (Fig. 3).
Reported HCV rates also differed by age group between
immigrants and non-immigrants; in immigrants cases
were found in all age groups. Those who were younger
(<15 years) and older (≥60 years) were more likely to be
immigrants whereas young and middle aged adults (20–
50 years) were more likely to be non-immigrants (Table 2).
Reported HCV rates were higher in immigrants from
Sub-Saharan Africa, East Asia and Pacific, Eastern Europe
and Central Asia, and South Asia (47.2, 43.7, 43.1 and
41.5/100,000 respectively) compared to those in non-
immigrants (27.1/100,000). Rate ratios ranged from 1.5 to
1.7 in these immigrant groups compared to non-
Table 2 Rates of Reported Cases of HCV per 100,000 from 1998 to 2008 (95% CI)
Characteristic Immigrants Non-immigrants RRa (95% CI)
N Reported rate (95% CI) N Reported rate (95% CI)
Overall 1922 23.2 (22.1–24.2) 18 940 27.1 (26.7–27.5) 0.85 (0.8–0.9)
Low/Intermediate income source countriesb 1733 32.3 (30.8–33.8) 1.2 (1.1–1.3)
Age groups (years)
< 15 12 2.08 (0.90–3.26) 105 0.79 (0.64–0.94) 2.63 (1.45–4.77)
15–19 17 5.15 (2.70–7.60) 297 6.28 (5.56–6.99) 0.82 (0.50–1.34)
20–29 133 14.1 (11.7–16.5) 2040 22.6 (21.6–23.5) 0.62 (0.52–0.74)
30–39 452 28.4 (25.8–31.2) 5114 53.1 (51.7–54.6) 0.54 (0.49–0.59)
40–49 588 38.3 (35.2–41.4) 6666 56.9 (55.6–58.3) 0.67 (0.62–0.73)
50–59 324 24.2 (21.5–26.8) 2705 28.5 (27.5–29.6) 0.85 (0.75–0.95)
60–69 193 19.6 (16.8–22.4) 1022 16.5 (15.5–17.5) 1.19 (1.02–1.38)
≥ 70 203 20.5 (17.7–23.4) 991 17.1 (16.1–18.2) 1.20 (1.03–1.39)
Sex
Female 891 21.1 (19.8–22.5) 60,004 17.0 (16.4–17.3) 1.25 (1.17–1.35)
Male 1031 25.3 (23.7–26.8) 12,936 37.8 (37.2–38.5) 0.67 (0.63–0.71)
Region of origin
Sub-Saharan Africa 152 47.2 (39.7–54.7) 1.7 (1.5–2.0)
East Asia and Pacific 443 43.7 (39.6–47.8) 1.6 (1.5–1.8)
Eastern Europe and Central Asia 287 43.1 (38.1–48.1) 1.6 (1.4–1.8)
South Asia 181 41.5 (35.4–47.5) 1.5 (1.3–1.8)
Middle East and North Africa 255 19.0 (16.7–21.4) 0.7 (0.6–0.8)
Latin America and Caribbean 205 14.1 (12.2–16.0) 0.5 (0.5–0.6)
US, Australia, and New Zealand 22 7.8 (4.5–11.1) 0.3 (0.2–0.4)
Western Europe 167 6.6 (5.6–7.6) 0.2 (0.2–0.3)
Countries of originc
Viet Nam 226 53.0 (45.9–60.1) 1.9 (1.7–2.2)
Pakistan 128 123.1 (101.6–144.6) 4.5 (3.8–5.4)
Cambodia 123 116.6 (95.6–137.5) 4.3 (3.6–5.1)
Romania 118 39.3 (31.9–46.6) 1.4 (1.2–1.7)
Haiti 111 13.0 (10.5–15.4) 0.5 (0.4–0.6)
Morocco 92 24.0 (19.0–29.0) 0.9 (0.7–1.1)
France 90 10.0 (7.8–12.1) 0.4 (0.3–0.5)
Egypt 60 21.7 (15.2–27.2) 0.8 (0.6–1.0)
Congo 55 151.0 (110.0–192.0) 5.6 (4.3–7.3)
Russia 36 53.5 (40.7–66.3) 2.0 (1.4–2.7)
aRate ratio comparing immigrants to non-immigrants, overall and in each category
bImmigrants from Western Europe, USA, Australia and New Zealand were excluded
cTop 10 Countries of Origin with the largest number of cases accounting for 54% of all immigrant cases
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immigrants (Table 2, Fig. 4). Reported HCV rates were
particularly high in immigrants from Congo, Pakistan,
Cambodia, Russia and Vietnam (Table 2).
Discussion
Immigrants from intermediate and high HCV prevalence
regions of Sub-Saharan Africa, Asia and Eastern Europe
had a 1.5–1.7-fold higher risk of HCV compared to non-
immigrants. Immigrants were older and less likely to be
male compared to non-immigrants cases and were diag-
nosed a mean of almost 10 years after arrival. Non-
immigrant cases were more likely than immigrant cases
to have behavioral co-morbidities such as problematic
alcohol or drug use, and to be HIV co-infected. The age
and sex adjusted HCV annual notification rate decreased
by almost 5% per year in non-immigrants but remained
relatively unchanged in immigrants between 1998 and
2008. As a consequence, the proportion of HCV cases
Fig. 2 Reported rates of HCV Cases/100,000 overall and in immigrants and non-immigrants (1998–2008). Between 1998 and 2008, the rate of
reported HCV cases adjusted for age and sex decreased by 4.89% per year in non-immigrants (95% CI = 4.85–4.93; p <0.001) compared to a 0.27%
annual increase in immigrants (95% CI = 0.03–0.51; p = 0.028)
Fig. 3 Reported rates of HCV cases/100,000 by sex and immigrant status (1998–2008). Between 1998 and 2008, the annual HCV cumulative
incidence adjusted for age decreased by 5.21% per year in non-immigrant females and by 4.72% in non-immigrant males compared to 0.60%
decrease in immigrant females and 1.18% annual increase in immigrant males (p <0.001)
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occurring in immigrants doubled over the study period
from 5 to 11%.
In our study, immigrants from Sub-Saharan Africa,
Asia and Eastern Europe had a higher HCV risk com-
pared to non-immigrants whereas immigrants from
North Africa and the Middle East and Latin America
and the Caribbean had a lower risk. The pattern of the
magnitude of HCV risk by region of origin in immi-
grants in our study reflects published epidemiology of
HCV in immigrants after arrival in host countries as well
as in their countries of origin [18, 24, 32]. HCV
seroprevalence is a reasonable surrogate measure for the
magnitude of HCV risk by region of origin and was used
as there were no comparative studies on HCV notification
rates in immigrants. HCV seroprevalence in Asia, Africa,
and Central and Eastern Europe is intermediate to high (2
to 4%) whereas it is low (1–2%) in Canada, Western
Europe, the US, Latin America and the Caribbean
and most countries in North Africa except Egypt and
Iraq [15, 19, 32]. Furthermore, high HCV reported
rates in immigrants from Congo (151/100,000 and RR
5.6), Pakistan (123; 4.5), and Cambodia (117; 4.3) and
are also consistent with global epidemiology as these
countries all have a high HCV seroprevalence ranging
from 2.3 to 6.7% [32].
We found major demographic and behavioral differ-
ences between immigrants and non-immigrants with
HCV. The demographic and behavior characteristics
of HCV in non-immigrants is consistent with the
characteristics of HCV cases in Canadian surveillance
data [15, 33]. HCV cases in Canada occur more frequently
in males and in current and previous intravenous drug
users and have a high risk of HIV co-infection [15, 33].
There is little data on HCV-infected immigrants in
Canada or other high income countries. Our findings are
similar to two other Canadian studies that also found that
immigrants with HCV were older, and were less likely
to be male or to have problematic drug use compared
to non-immigrants [34, 35]. In our study there were
significant differences in the HCV risk by age group
for immigrants and non-immigrants. Male and female
immigrants of all ages were found to have HCV, likely
reflecting the fact that exposure to contaminated
blood or unsafe medical procedures can occur at any
age and equally by gender. In non-immigrants, cases
were more likely to occur in young and middle age adults
and reflects the age group at highest risk for initiation and
active intravenous drug use [21]. Although the numbers
are small, immigrants <15 years of age were more likely to
have HCV than non-immigrants and may, in part, be due
to perinatal transmission.
The decreasing trend of reported HCV cases seen in
non-immigrants of 4.9% per year between 1998 and
2008 is consistent with the trends of notified HCV cases
in Canada, the US and Australia over this same period
[9, 33]. In contrast, rates of reported cases in immigrants
during this same period remained unchanged. This
could be explained by increased screening or reporting
of HCV in immigrants, newly acquired infections after
arrival, increased numbers of immigrants from at risk
countries arriving over the study period, or a steady rate
of imported HCV cases acquired in their country of ori-
gin in the setting of no routine post-arrival screening.
The latter is the most likely explanation given that HCV
screening in Canada during the study period was fo-
cussed on those with risk factors for HCV exposure such
as intravenous drug use and did not identify immigrants
as a high risk group [16, 36]. Furthermore, immigrants
are at low risk for HCV transmission after arrival in
Canada given the low prevalence of problematic drug
use in this group and the fact that the number of new
immigrants from at risk countries was stable during the
Fig. 4 Reported rates of HCV cases /100,000 (95% CI) by region of origin
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study period [20]. With this dataset we cannot eliminate
the possibility that immigrants may have become in-
fected with HCV after arrival in Canada during periods
of travel back to their countries of origin. Canadian
immigrants are less likely to access health care due to
several barriers including language, cultural difference or
infrastructure [37, 38]. This coupled with the lack of a
targeted HCV screening program may explain the 10-
year timeframe to diagnosis after arrival. These findings,
taken together, support the hypothesis that immigrants
are most likely to have been infected with HCV in their
countries of origin through unscreened blood products
or unsafe medical procedures rather than through inject-
ing drugs in Canada. The long asymptomatic period of
chronic HCV and lower health care access may explain
the long delay in diagnosis after arrival.
The major strengths of this study are that it is a large
population based sample spanning almost a 10-year
period in which immigration status was accurately
assigned through linkage with the landed immigration
database. All notified HCV cases were ascertained, were
laboratory confirmed, and acute and chronic cases were
identified and differentiated with standardized case
definitions. This study has some limitations including
the well-known underestimation of cases in a passive
surveillance system such as MADO. These data are also
influenced by health seeking behavior, non-nominal
reporting for some groups, and increased screening of
those at increased risk of hepatitis such as drug users.
Due to the anonymous reporting of certain cases or due
to missing demographic information or RAMQ num-
bers, almost 20% of cases did not link. Unlinked cases
were not differentially distributed between immigrants
and non-immigrants, thus calculated rates in this study
are under estimated by 20% in both groups, but without
misclassification between these groups. The increased
reported HCV rate observed between 2002 and 2004 is
likely due to the fact that HCV became reportable in
Quebec in 2002 and that there was enhanced surveil-
lance during this period of time [39]. We only have
access to data up until 2008 however, we expect that the
trends in case rates, underlying co-morbidities and time
to diagnosis after arrival for immigrants found in our
study would be similar to that after 2008. This is because
there are no targeted HCV screening programs for
immigrants in Quebec or Canada and this was the case
both before and 2008. The accuracy of diagnostic codes
to detect co-morbidities in RAMQ databases has not
been validated, however good accuracy has been shown
in other administrative databases [29]. Administrative
coding for problematic drug use is limited by the fact
that it is not possible to determine if drug use was intra-
venous or by another route and cases of prior drug use
(in those not actively using drugs), may not be detected.
We used the same codes for problematic drug use as
were used in a recently published study [28]. Despite
these limitations our data show important trends in
HCV in immigrants compared to non-immigrants that
are both plausible and are externally validated.
Untreated HCV is an enormous health and economic
burden in Canada and other low HCV prevalence coun-
tries. This burden is projected to increase over the next
decade unless the large pool of asymptomatic infected
individuals are detected and treated prior to developing
end stage liver disease [40, 41]. Eradication of HCV is
now within reach given the recent availability of highly
effective, well tolerated, short course, direct acting anti-
viral treatments [12]. Identifying all asymptomatic HCV-
infected individuals and successfully linking them to care
is a critical issue that will need to be addressed in order
to decrease the rising economic and individual burden
from HCV.
Conclusions
Immigrants born in intermediate and high HCV preva-
lence countries living in Canada are at increased risk for
HCV, less likely to have behavioral risk factors for HCV
and in the absence of a routine screening program were
diagnosed a mean of almost 10 years after arrival. These
immigrants are an important group to consider for
targeted HCV screening and early linkage to care.
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